antiviral strategy

This may sound strange but on some level antiviral drug research is "easy." Make that "easy compared to other therapeutic areas," because those who do research in the antiviral field – something I did for 10 years – have an advantage over scientis

I will soon be writing about the possibility of the first-ever direct-acting antiviral drug (DAAD) for respiratory syncytial virus (RSV), courtesy of Enanta Pharmaceuticals, a Massachusetts biotech company spe